Want to see SRZN full AI Analyst Report?
SRZN Stock Chart & Stats
$19.73
-$0.60(-3.04%)
At close: 4:00 PM EDT
$19.73
-$0.60(-3.04%)
Day’s Range― - ―
52-Week Range$9.03 - $35.00
Previous CloseN/A
Volume104.46K
Average Volume (3M)25.24K
Market Cap
$241.84M
Enterprise Value$218.81
Total Cash (Recent Filing)$106.91M
Total Debt (Recent Filing)$6.78M
Price to Earnings (P/E)―
Beta-0.19
Next Earnings
Aug 06, 2026EPS Estimate
-1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.33
Shares Outstanding11,610,371
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$43.33Price Target Upside119.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-13.06
Revenue Forecast (FY)$6.40M
Bulls Say, Bears Say
Bulls Say
Clinical-stage R&D FocusSurrozen’s concentrated clinical-stage focus on modulating Wnt signaling for tissue repair creates a durable strategic identity. A clear scientific niche and prioritized pipeline can generate high-value clinical milestones and partnership interest that drive long-term value beyond near-term revenues.
Governance ContinuityRecent stockholder votes reinforced board continuity, auditor ratification and say-on-pay frequency, lowering governance risk. Stable oversight and alignment with investors reduce execution uncertainty and support consistent strategic decision-making over the coming months.
Relatively Modest Absolute DebtDespite capital erosion, the company’s absolute debt level is modest, limiting near-term interest obligations. Lower fixed leverage provides some financial flexibility for a clinical-stage biotech while it pursues capital raises or partnerships to fund ongoing development.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow at tens of millions annually creates a structural funding requirement. Over multiple quarters this forces recurring external financings or dilutive equity issuances, increasing execution risk and dependence on capital markets or partners to sustain programs.
Negative Shareholders' EquityNegative equity reflects cumulative losses that have eroded the capital base, reducing balance-sheet cushion. This materially limits financial flexibility, makes traditional debt financing harder or costlier, and raises the severity of adverse outcomes if operating losses persist.
Low, Volatile Revenue BaseA small, uneven revenue stream relative to large R&D and operating costs means current operations are not self-sustaining. Volatility undermines margin predictability and makes reliance on milestone payments or financing necessary, delaying any clear path to sustainable profitability.
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $9.03 and its highest was $35.00 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $241.84M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Aug 06, 2026 which is in 5 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on May 06, 2026. The company reported -$11.65 earnings per share for the quarter, missing the consensus estimate of -$1.092 by -$10.558.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.29.
How many shares outstanding does Surrozen have?
Surrozen has 11,610,371 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$11.65 in its last earnings report, missing expectations of -$1.092. Following the earnings report the stock price went down -9.903%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Surrozen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.33 (119.63% Upside)
$43.33 (119.63% Upside)
Hedge Fund Trend
Increased
By 226.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.12%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$43.33
▲(119.63% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―
Ownership Overview
44.39% Insiders
1.90% Mutual Funds
0.37% Other Institutional Investors
47.03% Public Companies and
Individual Investors